We offer a suite of in vitro and in vivo discovery methods together with our engineered yeast to deliver therapeutic leads to our partners.
We improve and refine lead antibodies to turn good molecules into best-in-class molecules.
We offer a variety of bispecific formats that cover a wide range of biological functionality.
Using our proprietary platform we discover therapeutic antibodies that meet the highest standards of quality and developability.
We provide a full implementation of the Adimab Platform to enable your scientists to discover and optimize lead candidates within your existing workflow.
Board of Directors
News & Press Releases